• Immuron share price falls 27% on registered direct offering

    share price rollercoaster

    After days of consecutive growth, the Immuron Limited (ASX: IMC) share price is falling today following announcement of its registered direct offering. The share price is currently down 27% (at the time of writing) on the news. However, recent days have seen the Immuron share price on a wild ride, up 249% yesterday before today’s falls. Immuron is an Australian biopharmaceutical company focused on developing and commercialising oral medicine for the prevention and treatment of gut mediated pathogens.

    Why is the Immuron share price falling?

    The Immuron share price is today falling following the announcement that the company is raising US$20 million through a registered direct offering. The company announced it has entered into agreements with several healthcare-focused institutional investors for their participation in a registered direct offering of 1,066,668 American Depositary Shares (ADSs). Each of these ADSs represents 40 of the company’s ordinary shares. The price of these ADSs is $18.75. This is a premium with the company’s US dual listed cousin Immuron Ltd/S ADR (NASDAQ: IMRN) currently trading at US$14.81. However the large drop in the Immuron share price is no doubt due to the considerable dilution of the share value the offering causes. The offering is set to close around 23 July.

    Immuron intends to use the net proceeds from this offering to fund its Research and Development and preclinical and clinical programs. The funding is also being used to support marketing initiatives surrounding the company’s flagship product, Travelan, and provide ongoing working capital.

    What now for Immuron?

    In recent days there has been plenty of news out of Immuron. On Monday, the Immuron share price shot 11% higher after receiving FDA guidance for its new developmental drug. Subsequently in further exciting news, the Immuron share price rose nearly 250% yesterday as its flagship drugs, Travelan and Protectyn, demonstrated antiviral activity against COVID-19 in laboratory testing. It is not surprising today that we are seeing a pull back in the share price as it becomes heavily diluted. While this may be seen as a negative, it can also be seen as investors having confidence in the company moving forward, investing their money at higher prices.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    The post Immuron share price falls 27% on registered direct offering appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/32HHynZ

  • Should you buy ASX retail shares in July?

    two people walking along carrying shopping bags

    Data is the key for ASX retail shares in 2020. That’s what I think is the big message after the value of Australia’s retailers surged on Tuesday.

    Positive news about coronavirus vaccine candidates pushed the S&P/ASX 200 Index (ASX: XJO) as a whole 2.6% higher on Tuesday.

    However, ASX retail shares received a particularly strong boost from the Federal Government’s JobKeeper and JobSeeker extensions.

    What’s happening with JobKeeper and JobSeeker?

    Prime Minister Scott Morrison announced a range of changes to the existing stimulus programs.

    JobKeeper payments will be reduced to $1,200 for full-time workers, down from $1,500 at the moment. That will run until the end of 2020 and then drop to $1,000 per fortnight from January 3.

    The part-time worker payment will be reduced from $1,500 to $750 per fortnight after September before dropping to $650 per fortnight in 2021.

    The new end date for ‘JobKeeper 2.0’ will be 28 March 2021.

    The $550 JobSeeker supplement will be reduced to $250 per fortnight after September. That means total payments will be reduced from $1,115 to $815.

    Why is that good news for ASX retail shares?

    Yesterday I wrote about the potential impacts of this week’s action-packed spate of economic updates.

    I wrote that an extension of JobKeeper and JobSeeker could help boost ASX 200 retail shares like JB Hi-Fi Limited (ASX: JBH) and Super Retail Group Ltd (ASX: SUL) higher.

    That proved to be the case on Tuesday, with JB Hi-Fi shares surging 2.0% and Super Retail jumping 3.7%. Shares in retail REIT Scentre Group (ASX: SCG) also rocketed higher on the news, closing up 3.3% at $2.17 per share.

    Retail billionaire Solomon Lew shared a similar view according to an article in the Australian Financial Review (AFR).

    Mr Lew described ‘JobKeeper 2.0’ as a ‘big shot in the arm for the Australian workforce and broader economy’. Low unemployment is good for sales while the extra cash is helping retail stores continue operations.

    Is now a good time to buy?

    I think the answer to this really depends on the August earnings season. The JB Hi-Fi share price has climbed 14.2% this year on the back of strong sales. This says to me that investors are already pricing in a strong sales result in 2020.

    However, the JobKeeper extension is good for business. That means more cash in the economy and less of a drain on expenditure.

    If we see an Aussie retailer like Super Retail outperform with respect to earnings, I think ASX retail shares will finish the year strongly.

    Any signs of persistent sales growth or operational streamlining could push ASX retail shares higher in August and September.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Super Retail Group Limited. The Motley Fool Australia has recommended Scentre Group. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Should you buy ASX retail shares in July? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3jq6zd7

  • Where to invest $20,000 into ASX shares right now

    Dividends

    At the weekend I looked into how investments of $20,000 in a number of popular ASX shares fared over the last 10 years.

    Given the success of these investments, I thought I would now look at a few shares which I feel investors ought to consider investing $20,000 into today for the next decade.

    Here why I think these three ASX shares could provide strong returns for investors:

    Altium Limited (ASX: ALU)

    I think this electronic design software platform provider would be a great place to invest $20,000. I’m a big fan of Altium due to its exposure to the Internet of Things (IoT) boom. The rapidly growing IoT market should drive strong demand for its offering in the future. This is because the majority of these connected devices require software like Altium Designer and Altium 365 during the design process. Management appears confident in its outlook and is aiming for 100,000 subscriptions by FY 2025. This compares to the 50,000 subscriptions it is achieved in FY 2020. Combined with its other growing businesses, such as NEXUS and Octopart, I believe the future is bright for Altium.

    Kogan.com Ltd (ASX: KGN)

    Another ASX share to consider investing $20,000 into is Kogan. It is a growing ecommerce company and Australia’s version of Amazon. I think it is a great long term option for investors due to the growing popularity of its website and the continued shift to online shopping in the country. Prior to the pandemic, an estimated ~10% of retail spending was being made online in Australia. I expect this number to grow materially over the next decade and underpin strong sales and profit growth for Kogan.

    NEXTDC Ltd (ASX: NXT)

    A final ASX share for investors to consider investing $20,000 into is NEXTDC. I think the data centre operator’s shares could provide strong returns for investors over the 2020s due to its exposure to the rapidly growing cloud computing market. Thanks to the shift to the cloud, NEXTDC’s world class data centres have been experiencing a material increase in demand for capacity over the last few years. And with more infrastructure expected to shift over in the next decade, I believe it is well-positioned to profit greatly.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    James Mickleboro owns shares of NEXTDC Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Altium and Kogan.com ltd. The Motley Fool Australia has recommended Kogan.com ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Where to invest $20,000 into ASX shares right now appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/32GS3Yx

  • Beach Energy share price storms higher despite Q4 sales slump

    oil company share price

    In morning trade the Beach Energy Ltd (ASX: BPT) share price is storming higher following the release of its fourth quarter update.

    At the time of writing the energy producer’s shares are up 5% to $1.56.

    How did Beach Energy perform in the fourth quarter?

    Beach Energy reported fourth quarter total production of 6.8 MMboe, which brings its full year total production to a total of 26.7 MMboe. This represents a 2% increase on FY 2019 pro forma production of 26.2 MMboe.

    FY 2020 oil production came in at 8.8 MMbbl, which was up 27% over FY 2019. This was in-line with its guidance of 8.7 MMbbl to 9.2 MMbbl.

    However, despite its solid oil production, its overall production was a touch short of its full year production guidance.

    Management explained that the effects of COVID-19 impacted the pace of new Western Flank well connections and gas demand during the quarter, resulting in its production being 1% below guidance.

    Sales suffer from oil price collapse.

    Beach Energy’s sales took a big hit during the fourth quarter following the collapse in oil prices.

    It recorded fourth quarter sales revenue of $320 million, which was 26% lower than the prior quarter. This was driven by a 37% decline its realised oil price to $46.90 a barrel and offset slightly by cost saving measures.

    Management continues to target further operating cost reductions to help offset the impact of lower oil prices. It is aiming for a 10% reduction in field operating costs/boe in FY 2021 relative to FY 2019 levels of $9.30/boe.

    Overall, Beach Energy ended FY 2020 with $50 million net cash and access to $500 million in liquidity.

    FY 2020 earnings to fall short of guidance.

    In light of the above, management warned that it expects its FY 2020 underlying EBITDA to be marginally below its prior guidance of $1,175 million.

    This is primarily due to oil/liquids prices, the impact of COVID-19 on production, and includes the costs relating to the Tawhaki 1 exploration well.

    No guidance was given with today’s update. However, management intends to release its FY 2021 guidance and a five year outlook with its FY 2020 results in August.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Beach Energy share price storms higher despite Q4 sales slump appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/39fQ8LI

  • Baby Bunting share price jumps after reporting strong growth despite COVID-19

    shares high

    The Baby Bunting Group Ltd (ASX: BBN) share price has jumped higher following the release of its preliminary unaudited full year results.

    In morning trade the baby products retailer’s shares are up 6% to $3.33.

    How did Baby Bunting perform in FY 2020?

    Baby Bunting was a strong performer in FY 2020 despite the disruption caused by the pandemic in the second half.

    According to the release, Baby Bunting delivered total sales of approximately $405 million in FY 2020 This represents growth of around 12% and was driven by very strong second-half comparable store sales growth.

    Comparable stores sales grew 10.5% during the second half, lifting full year comparable store sales growth to 4.9%. This was largely the result of its online business, with comparable store sales growth from its bricks and mortar stores coming in at 2.5% for the year.

    Online sales (including click & collect) grew 39% during the year and now make up 14.5% of total sales.

    In respect to earnings, Baby Bunting expects to report pro forma earnings before interest, tax, depreciation and amortisation (EBITDA) of between $33 million and $34 million. This represents growth of between 22% to 25% on FY 2019’s EBITDA result.

    On the bottom line, the retailer is expecting to report pro forma net profit after tax of between $18.5 million and $19.5 million. This will be year on year growth of between 29% and 35%.

    On a statutory basis, Baby Bunting expects a net profit after tax of between $9.5 million to $10.5 million. This will be down from $11.6 million a year earlier.

    This statutory result includes the non-cash impact of employee equity incentive expenses, significant transformation project expenses, and the impairment of the carrying value of its investment in its digital commerce technologies. Pro forma EBITDA also excludes the impact of AASB 16 lease accounting.

    “Very positive results”.

    Baby Bunting’s CEO and Managing Director, Matt Spencer, was pleased with the company’s performance during these challenging times.

    He said: “These are very positive results, in particular given the impact of the COVID-19 pandemic on communities in Australia. During the year, all of our stores remained open and our Team worked incredibly hard to adapt how we operated to ensure that we continue to support new and expectant parents in these challenging times. We have seen the business continue to grow in FY20 and I am confident that growth will continue in FY21.”

    “As the ongoing restrictions in Melbourne and surrounding areas indicate, COVID-19 is likely to have an impact into FY21 in ways that may be unexpected. I am confident that our business can respond to new challenges as we did in the second half of FY20. To date, trading in FY21 has continued to be positive,” he added.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Baby Bunting share price jumps after reporting strong growth despite COVID-19 appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/39fjQkb

  • Moderna: Tricky Road Ahead for mRNA-1273, Says 5-Star Analyst

    Moderna: Tricky Road Ahead for mRNA-1273, Says 5-Star AnalystInvestors of Moderna (MRNA) slept soundly last weekend, as shares ended each session in the green during the week. Saving the best for last, on Friday July 17, Moderna posted a 16% uptick after it was revealed that the European Union (EU) might purchase Moderna’s experimental COVID-19 vaccine. The latest surge has sent the stock to a record high, having added 310% of muscle since the turn of the year.With a Phase 2 study currently in progress, and a Phase 3 trial of mRNA-1273 set to begin on July 27, Oppenheimer analyst Hartaj Singh sees a rocky path ahead, yet remains optimistic.“MRNA's valuation, in our view, is reflecting an approval and fast uptake of mRNA-1273, in line with other historical biotech comps. Pricing dynamics, potential donation of free vaccine and distribution of mRNA-1273 are non-trivial issues. We believe these can be navigated, but transit could be choppy. As the leader in the COVID-19 vaccine space, we continue to find MRNA attractive,” said the 5-star analyst.Should mRNA-1273 gain approval, which is by no means a certainty and given a 50% probability of success by Singh, it is expected to generate sales of $5 billion by 2023. However, in order for that to become a reality, there are “many hurdles that MRNA needs to navigate over the next 3-6 months.”These hurdles include the drug’s pricing. Other big pharma names such as Johnson & Johnson and AstraZeneca have said they might distribute their vaccines “at cost” while the virus still rages on. Additionally, with Moderna’s use of shareholder capital to produce mRNA-1273 “at risk,” this means “threading the pricing needle for mRNA-1273 will require finesse.” Add into the mix the possibility that the vaccine might be donated to developing countries – like Gilead has done with its viral treatment, remdesivir – and pricing becomes further complicated.Lastly, there are the distribution logistics. Singh believes Moderna will “work closely with US governmental and international agencies to distribute mRNA-1273 in an equitable manner,” and might even search for a partner to work with on the commercial side.Despite the variables, all in all, Singh concludes these are “high-quality problems, and we continue to find MRNA attractive.”Therefore, Singh reiterated an Outperform rating along with a $108 price target. There’s 33% upside in the cards, should Singh’s target be met over the next 12 months. (To watch Singh’s track record, click here)What does the rest of the Street make of the high-flying biotech’s prospects? Based on 13 Buys and 3 Holds, Moderna has a Strong Buy consensus rating. In addition, the $93.79 average price target implies upside potential of 17%. (See Moderna stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/2ZOoMJH

  • TPG and 1 other quality ASX 200 share to buy right now

    blackboard drawing of hand pointing to the words buy now

    I believe that buying quality ASX 200 shares is the best way to build your wealth over the long term. This is especially this case with interest rates looking to remain at historic lows for several years to come.

    Here we look at 2 ASX 200 shares that I believe could make good additions to your share portfolio right now. Here’s why I recommend them:

    2 ASX 200 shares to add to your portfolio

    TPG Telecom Ltd (ASX: TPG)

    TPG has struggled in recent years. This is partly due to the tight operating margins it faced when purchasing wholesale fixed broadband services from the National Broadband Network (NBN). This is reflected in its NBN average revenue per user (ARPU) figure. NBN ARPU has been steadily declining in recent years. It has dropped from $67.4 per month in 1H19 to $66.4 per month in 1H20.

    However, I believe that TPG’s merger with Vodafone places it in a position to turn its fortunes around and drive higher profitability. TPG-Vodafone is now more strongly placed to compete with its two largest operators in the Australian telco market: Telstra Corporation Ltd (ASX: TLS) and Optus. In particular, the newly merged entity is well positioned to roll out a competitive 5G offering on Vodafone’s existing nationwide mobile network.

    Transurban Group (ASX: TCL)

    Transurban has unsurprisingly seen a reduction in traffic on its toll roads during the coronavirus pandemic. This triggered a sharp decline in it share price during the early phase of the crisis. The Transurban share price fell from $16.33 on 11 February to $10.50 on 20 March, a decline of 36%.

    However easing of COVID-19 restrictions is resulting in a gradual recovery in traffic on Transurban’s tollways in local markets over the past few months. The company reported a steady recovery in traffic across its Australian operations, from mid April up until late June.

    Melbourne of course is now in full lockdown mode again, and this will definitely slow down Transurban’s recovery over the rest of the year. However, I still remain optimistic about Transurban’s long-term  future. The coronavirus pandemic will eventually subside, with traffic levels returning to normal. Furthermore, Transurban’s two largest area of operation, Sydney and Melbourne, both have fast growing populations. They also both have expanding road systems that may require additional toll roads in the years to come. 

    With the Transurban share price well below pre-COVID-19 levels, I believe that now could be a good opportunity to snap up some shares in this toll-road operator.

    Foolish takeway

    TPG and Transurban are two quality ASX 200 shares that I would be happy to add my portfolio right now. Both have faced recent challenges, however are now well placed for long-term growth.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Phil Harpur has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Transurban Group. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post TPG and 1 other quality ASX 200 share to buy right now appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/30AkUen

  • A Bullish Alibaba Will Depend on Ant’s Bottom Line

    from Yahoo Finance https://ift.tt/3hoSniS

  • Flood Of Unusual Boeing Call Buying Following FAA 737 Max Update

    Flood Of Unusual Boeing Call Buying Following FAA 737 Max UpdateBoeing Co (NYSE: BA) shares traded higher by 3.4% on Tuesday after the Federal Aviation Administration released an update on the grounded 737 Max suggesting the jet could be cleared for takeoff in the fourth quarter, a later return date than Boeing has been anticipating.A flurry of large Boeing option trades were mixed in nature as investors struggle to determine just how much upside the stock has in a post-coronavirus world.The Boeing Trades: On Tuesday morning, Benzinga Pro subscribers received 26 option alerts related to unusually large trades of Boeing options. Here are a handful of the biggest: * At 10:22 a.m., a trader bought 1,000 Boeing call options with a $180 strike price expiring on Aug. 21 at the ask price of $14. The trade represented a $1.4 million bullish bet. * At 10:25 a.m., a trader bought another 988 Boeing call options with a $180 strike price expiring on Aug. 21 at the ask price of $13.801. The trade represented a $1.36 million bullish bet. * At 10:41 a.m., a trader sold 600 Boeing put options with a $160 strike price expiring on Nov. 20 at the bid price of $16.851. The trade represented a $1.01 million bullish bet. * At 12:25 p.m, a trader bought 974 Boeing call options with a $180 strike price expiring on Aug. 21 near the ask price at $14.20. The trade represented a $1.38 million bullish bet.Of the 26 total large Boeing option trades on Tuesday morning, 10 were calls purchased at or near the ask or puts sold at or near the bid, trades typically seen as bullish. The other sixteen trades represented calls sold at or near the bid or puts purchased at or near the ask, trades typically seen as bearish.All four of the largest trades of the day, all over $1 million in value each, were bullish.Why It's Important: Even traders who stick exclusively to stocks often monitor option market activity closely for unusually large trades. Given the relative complexity of the options market, large options traders are typically considered to be more sophisticated than the average stock trader.Many of these large options traders are wealthy individuals or institutions who may have unique information or theses related to the underlying stock.Unfortunately, stock traders often use the options market to hedge against their larger stock positions, and there's no surefire way to determine if an options trade is a standalone position or a hedge. In this case, given the relatively large sizes of the largest Boeing trades, they could potentially represent institutional hedging.Backlog Shrinking: Boeing has been one of the hardest-hit U.S. companies during the COVID-19 downturn. On Tuesday, the FAA said it will be issuing a Notice of Proposed Rulemaking related to the 737 Max "in the near future." Following the release, CNBC's Phil LeBeau said the timeline included in the proposal suggests the Max could be cleared by the fourth quarter, a later return date than Boeing had been targeting.Boeing reported another 60 net 737 Max order cancellations in the month of June, bringing total net cancellations in the first half of 2020 up to 323 planes. In the first half of 2019, Boeing's net order total was +21 planes. Boeing's total order backlog shrank to 4,552 planes in June.Back on March 20, Boeing announced it was suspending its dividend and share buybacks in an effort to weather the COVID-19 downturn. In May, the company raised $25 billion via a bond offering to help shore up its liquidity position during the outbreak.Boeing shares are now down 44.6% year to date, but up 70.8% since the market bottomed on March 23. On July 17, Wolfe Research downgraded Boeing from Peer Perform to Underperform with a $149 price target and said the firm is concerned about additional 737 Max cancellations and near-term demand for widebody planes. BA Chart by TradingView new TradingView.widget( { "width": 680, "height": 423, "symbol": "NYSE:BA", "interval": "D", "timezone": "Etc/UTC", "theme": "light", "style": "1", "locale": "en", "toolbar_bg": "f1f3f6", "enable_publishing": false, "allow_symbol_change": true, "container_id": "tradingview_d1039" } ); Benzinga's Take: Boeing's stock has rallied significantly in large part due to relief that the company will remain solvent in the near term. However, additional upside for the stock from here may be limited if the second wave of the COVID-19 outbreak continues to hurt the air travel industry and Boeing keeps losing more orders than it is gaining.Related Links:Visa Option Trader Makes .6M Bet On 15% Upside How To Read And Trade An Option AlertSee more from Benzinga * Here's How Large Option Traders Are Playing Boeing As Order Backlog Shrinks * Dave Portnoy Trades And Entertains, But Whitney Tilson Says He's Reminiscent Of The 'Proverbial Shoeshine Boy'(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/32Iej4c